an no est disponible de forma generalizada
All pharmacological treatments for weight management should be used as part of a comprehensive, multidisciplinary programme that includes dietary guidance, physical activity support, and behavioural intervention, in line with NICE recommendations
Abstract Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging
Clin Gastroenterol Hepatol 2025;23:739-47.ArticlePubMed 22
10.21608/zjfm.2019.11338.1027 37 HoaglandD
In principle, synergy is plausible in a few situations: Complementary pathways (e.g., appetite control + strength training adherence) Non-overlapping side-effect profiles Clear outcome tracking (so you can actually attribute effects) Where it tends to fall apart: Redundancy (two agents trying to push the same pathway) Hormonal axis pressure (especially GH/IGF-1 axis stacking) Long timelines with weak evidence (people run stacks for months because its peptides, not because outcomes justify it) For the rest of this article, Ill treat each stack as a clinical hypothesis and ask a simple question: If this were my patient, what would I be confident saying based on human evidenceand what would I label unknown? The 7 stacks people search for most (and what the evidence really supports) Quick comparison table Now, lets go stack by stack